1. Home
  2. Sistema de Salut de Catalunya
  3. Vall d'Hebron Institut d'Oncologia – VHIO
  4. Articles científics - VHIO
  5. View Item

Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis

To access the full text documents, please follow this link: http://hdl.handle.net/11351/6441

Author

Cortés Castan, Javier

Twelves, Chris

Other authors

Institut Català de la Salut

[Cortes J] IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Twelves C] Leeds Institute of Medical Research at St James's, University of Leeds and Leeds Teaching Hospitals Trust, Leeds, UK

Vall d'Hebron Barcelona Hospital Campus

Publication date

2021-10-22T06:44:47Z

2021-10-22T06:44:47Z

2020-07



Share

Abstract

Càncer de mama avançat; Eribulina; Supervivència global

Cáncer de mama avanzado; Eribulina; Supervivencia global

Advanced breast cancer; Eribulin; Overall survival

In a pivotal phase 3 study (Study 305), eribulin mesylate improved overall survival (OS) in patients with previously treated metastatic breast cancer (MBC) compared with treatment of physician's choice (TPC). This post hoc, pooled subgroup analysis of two phase 3 studies (Study 305 and Study 301) reports the influence of the number of prior chemotherapy regimens (0-6) on OS in patients with locally advanced/MBC randomized to eribulin versus TPC/capecitabine. Patients with ≤ 3 prior chemotherapies for locally advanced/MBC had longer median OS with eribulin (15.3 months) versus control (13.2 months; hazard ratio, 0.858; P = .01).

This support was funded by Eisai Inc, Woodcliff Lake, NJ, USA.

Document Type

Article

Published version

Language

English

Subjects and keywords

Mama - Càncer - Quimioteràpia; Mama - Càncer - Prognosi; DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Disease-Free Survival; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia sin enfermedad

Publisher

Wiley

Related items

Breast Journal;26(7)

https://doi.org/10.1111/tbj.13686

Recommended citation

This citation was generated automatically.

Export

DIDL MARC MARC_CCUC METS OAI_DC ORE QDC RDF

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)

Articles científics - VHIO [468]